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Abstract
Rationale Delivering orally bioavailable drugs to rodents is an important component to investigating that route of administration
in novel treatments for humans. However, the traditional method of oral gavage requires training, is stressful, and can induce
oesophageal damage in rodents.
Objectives To demonstrate a novel administrative technique—palatable gelatine tablets—as a stress-free route of oral delivery.
Methods Twenty-four male Lister hooded rats were sacrificed for brain tissue analysis at varying time-points after jelly admin-
istration of 30 mg/kg of the wake-promoting drug modafinil. A second group of 22 female rats were tested on locomotor activity
after 30 mg/kg modafinil, or after vehicle jellies, with the locomotor data compared to the brain tissue concentrations at the
corresponding times.
Results Modafinil was present in the brain tissue at all time-points, reducing in concentration over time. The pattern of brain
tissue modafinil concentration is comparable to previously reported results following oral gavage. Modafinil-treated rats were
more active than control rats, with greater activity during the later time-periods—similar to that previously reported following
intraperitoneal injection of 40 mg/kg modafinil.
Conclusions Palatable jelly tablets are an effective route of administration of thermally stable orally bioavailable compounds,
eliminating the stress/discomfort and health risk of oral gavage and presenting as an alternative to previously reported palatable
routes of administration where high protein and fat levels may adversely affect appetite for food reward, and uptake rate in the
gastrointestinal tract.
Keywords Modafinil . Oral administration . Pharmacokinetics . Locomotor activity
Introduction
Administration of pharmacological agents in experimental an-
imals, to investigate effects on the brain and behaviour, is per-
formed via a variety of routes—e.g. intra-cerebrally (via im-
planted catheters in the brain); by injection (intraperitoneal—
i.p.; subcutaneous—s.c.; intravenous—i.v.; or intramuscular—
i.m.); transdermally (via a skin-patch; or onto a mucous mem-
brane); by inhalation; orally (by gavage—insertion directly into
the stomach; or through mixing with food or drink). The route
chosen will impact the pharmacokinetics (e.g. absorption rate),
and therefore influence the timing and magnitude of any be-
havioural effect, but there are also other practical considerations
when selecting a particular route of administration. For exam-
ple, there may be secondary behavioural effects of giving the
drug: an interruption of ongoing behaviour might distract or
arouse the animal, such that behaviour after drug administration
changes irrespective of any pharmacological effect of the drug.
This is likely to be a particular problem if the route of admin-
istration causes pain or discomfort, as is evident with needle-
sticks and gavage. Oral gavage has been reported to induce
significant increases in heart rate 2–5 h post-gavage and in-
crease faecal corticosterone (Walker et al. 2012; Bonnichsen
et al. 2005); and stress-related arousal will have behavioural
consequences. Yet oral administration is a desirable route to
explore, given the ultimate preference for such in treatments
for human conditions, so establishing stress-free oral route for
laboratory animals is a priority.
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Walker et al. (2012) have shown that mice which voluntarily
consumed a ‘pill’ made from Transgenic Dough Diet™
(Bioserve, Inc.) did not show a stress response compared to
oral gavage. Whilst it is simple to knead drugs into the dough,
there are disadvantages to using this diet: it is designed for
rodents with chewing, dental or mobility impairments and
therefore whilst highly palatable, is also high in protein and
fat. This makes it less useful for studies that measure behaviour
motivated by food and in instances where uptake may be af-
fected by food in the gastrointestinal tract. Other low-stress
palatable techniques, such as adding drugs to condensed milk
(Murphy et al. 2015), are similarly disadvantaged by high pro-
tein, fat and sugar content; whilst training rats to drink from a
syringe (e.g. Mar et al. 2017; Robinson 2012) requires a time
component for both training and actual experimental dosing.
In the present study, we used a flavoured, but fat-/sugar-
free, gelatine Bjelly^ tablet (previously described in
Bowman et al. 2014) to orally administer modafinil
(2-[(Diphenylmethyl)sulfinyl]acetamide) to rats. Modafinil
is a stimulant drug used in the treatment of narcolepsy
and excessive sleepiness (Bastuji and Jouvet 1988; Edgar
and Seidel 1997). It has gained particular interest for its
unique wake-promoting effects without exerting typical
amphetamine-like side-effects, such as sleep rebound, and
neither does it have abuse potential (Edgar and Seidel 1997;
Deroche-Gamonet et al. 2002; Touret et al. 1995; Leith and
Barrett 1976; Koob and Bloom 1988).
Modafinil has also been investigated for its potential
cognitive-enhancing effects, where it has been linked to in-
creased performance and accuracy on a variety of cognitive
tasks in both patients with schizophrenia and healthy adults
(digit span task, CANTAB-Stroop), as well as in experimental
animals performing visual attentional tasks and T-maze-serial
reversal learning (Minzenberg and Carter 2008; Turner et al.
2003; Randall et al. 2005; Morgan et al. 2007; Beracochea
et al. 2002). We have recently observed effects of 30 mg/kg
modafinil, administered i.p. prior to testing, on Lister hooded
rat behavioural flexibility during the intradimensional/
extradimensional (ID/ED) attentional set-shifting task
(Chase, Tait and Brown, unpublished observations).
To determine the viability of the oral jelly method of ad-
ministration, we investigated the effects of a single dose of
modafinil on locomotor activity (LMA) and brain tissue con-
centration. Previous studies have shown that various doses of
modafinil in the rat elicit either an outright increase in LMA
(75–600 mg/kg; Ishizuka et al. 2008; Rowley et al. 2014), or a
slowed reduction (40 mg/kg; Simon et al. 1996), compared to
controls. Using an electroencephalogram (EEG), Edgar and
Seidel (1997) observed that their (100–300 mg/kg)
modafinil-induced LMA ‘increase’ derived from time spent
awake—i.e. that BLMA intensity^ (LMA per time spent
awake) did not change. Based on our prior behavioural obser-
vations after 30 mg/kg i.p., the robust effect of 40 mg/kg i.p.
on LMA (Simon et al. 1996), and an established pharmacoki-
netic profile after 32 mg/kg by oral gavage (Waters et al.
2005), we investigated oral jelly administration of 30 mg/kg
modafinil—predicting it would induce a similar LMA profile
to that observed by Simon et al. (1996): a reduction in LMA
over time that was slower than that observed in controls. We
also explored modafinil concentrations in brain tissue to es-
tablish a pharmacokinetic profile for the oral jelly administra-
tion route after the same dose, to allow comparison to the oral
gavage route.
Methods
Animals
Forty-six (24 male; 22 female) naïve Lister hooded rats
(Charles River, UK) were group-housed, but segregated by
sex, and maintained on a 12 h light/dark schedule (lights-on
at 7 am). They were maintained on a diet of 15–20 g of stan-
dard laboratory chow each day with water available ad
libitum. The male rats weighed between 480 and 630 g and
the females weighed between 185 and 250 g over the course
of the experiment. All experimental procedures were carried
out in accordance with the UK Animals (Scientific
Procedures) Act 1986 and EU Directive 2010/63/EU.
Drug preparation and habituation
Modafinil was administered to the rats orally, suspended in a
palatable gelatine (jelly) tablet as the vehicle. The jellies were
made by heating a water bath to ~ 70 °C, then placing into the
water bath a beaker containing 50 ml of flavoured, sugar-free,
fruit juice concentrate (Robinsons Squash, Britvic PLC, UK)
and adding 12 g gelatine (Dr. Oetker, UK). The mixture was
stirred until the gelatine was fully dissolved. Modafinil
(Sequoia Research Products Ltd., UK) doses (30 mg/kg) for
individual rats were weighed out and added to the bottom of
2 ml wells in a plastic mould. The gelatine solution was then
pipetted into the wells (1.5 ml/well), and the mixture carefully
stirred with a small pipette tip to suspend the modafinil.
Vehicle jellies were made using the same procedure, but with-
out modafinil. The plastic mould was then placed in a fridge
(3–5 °C) overnight for the jellies to cool and set. Once the
jellies were set, they were removed from the moulds and
stored in the fridge in airtight containers.
The rats were habituated to vehicle jellies before data col-
lection: rats were placed individually in a large home-cage and
presented with a jelly in a small ceramic pet food bowl, and
left until they had fully consumed it. This was repeated once
per day until rats were eating the jelly within 5 min, which was
usually by the third day.
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Experiment 1: the pharmacokinetic profile of orally
administered modafinil
Drug administration
On the day of the experiment, the 24 male rats were single-
housed and presented with modafinil-containing jellies. The
time at which a rat finished eating the jelly was recorded
(typically no more than 5 min after it had started eating), and
at specific time-points after that (15, 30, 45, 60, 75, 90, 120
and 150 min; n = 3 per time-point) rats were sacrificed by
decapitation. After decapitation, brains were extracted from
the skull, the cerebellumwas removed, and then the remainder
was bisected in the sagittal plane. Each hemisphere was
weighed and then rapidly frozen by immersion in isopentane
(Sigma-Aldrich, UK) chilled by dry ice. The hemispheres
were then wrapped in aluminium foil, individually placed in
homogenisation tubes and stored at − 80 °C.
Post-mortem bioanalysis
Rat brain concentrations of modafinil were determined using
ultra performance liquid chromatography (UPLC) coupled to
tandem mass spectrometry (MS/MS). Brain samples were
prepared by homogenising the brains 1:3 (v/v) with a mix-
ture of water, 2-propanol and dimethyl sulfoxide (DMSO;
50:30:20 v/v/v). Samples were precipitated with acetonitrile
and DMSO (80:20 v/v) containing internal standard.
Following centrifugation, 10 μl was injected onto the chro-
matographic system consisting of an Aria TLX2 system
(Thermo Fisher Scientific Inc., MA, USA) connected to a
Thermo TSQ Quantum Ultra triple quadrupole mass spec-
trometer. Analytical separation was achieved using a
Kinetex C18 column (50 × 2.1 mm, 2.6 μm particles;
Phenomenex, CA, USA). The mobile phase consisted of
0.01% formic acid in acetonitrile and 0.1% formic acid in
water pumped through the column using a 3-min gradient.
Modafinil was detected at a parent > daughter mass to
charge ratio (m/z) of 274.01 > 167.00. The retention time
was 1.27 min. The peak area correlated linearly with the
brain concentration of the analyte in the range of 40–
4000 ng/g brain.
Experiment 2: the effects of orally administered
modafinil on locomotion activity
Test procedure
On the day of testing, starting 4 h after lights on, the 22 female
rats were habituated to a 7 × 15 LED infrared actimeter
(Hamilton-Kinder MotorMonitor; Ponway, CA, USA) for
60min. Following actimeter habituation, a jelly was presented
in a ceramic bowl directly into the actimeter. Jellies were
administered 5 h after lights-on (Circadian time 5 (CT5),
where CT0 is lights-on), as it has been observed that sleep
loss can impact stimulant drug efficacy (Edgar et al., 1991;
Roehrs et al., 1989). CT5 (in 12 h light/dark schedule) in
particular, yields the least interference from the high variabil-
ity in wakefulness due to large amounts of sleep (< CT5) and
the normal circadian wakefulness found closer to lights-off (>
CT5) (Edgar & Seidel, 1997). Precisely 15 min from the point
the rat started eating the jelly (with all jellies consumed within
5 min), the actimeter was reset, and testing commenced. LMA
data were compiled to investigate time-periods of interest (15–
30, 30–45, 45–60, 60–75, 75–90, 90–105, 105–120, 120–135,
135–150 and 150–160 min). Timings were aligned so that
sacrifice time-point ‘15 min’ from experiment 1 falls within
the first 5 min of the ‘15–30 min’ time-period from experi-
ment 2 (and so on for the remaining time-points/periods—
with the last two sacrifice time-points from experiment 1 fall-
ing within the last four time-periods of experiment 2).
Counterbalancing
Each rat was tested twice, with 11 rats each receiving
modafinil and vehicle jellies in each test, and rats receiving
modafinil and vehicle jellies once each. There was a minimum
of 5 days between tests to allow for washout of modafinil.
Data compilation and analysis
The LMA data were configured as LMA/min over 10 time-
periods (15–30, 30–45, 45–60, 60–75, 75–90, 90–105, 105–
120, 120–135, 135–150 and 150–160 min), and analysed by
ANOVA using SPSS v. 22 with the dependant variable being
the total number of infrared beams crossed within the ob-
served time-period. There were two within-subjects factors:
dose (two levels: modafinil and vehicle), and time-period
(ten levels: as above). A second ANOVA, with two within-
subjects factors: test (test 1 and test 2) and time-period was
used to confirm that rats’ performance was not affected by test
order. Greenhouse-Geisser corrections were applied for sphe-
ricity violations.
Results
Experiment 1: the pharmacokinetic profile of orally
administered modafinil
Modafinil was detected in the brain tissue at all time-points
(Fig. 1). A rapid uptake in the brain was observed with mean
concentrations in the range of 300–400 ng/g during the first
hour after drug intake, where after a gradual decrease in brain
concentrations was observed over time.
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Experiment 2: the effects of orally administered
modafinil on locomotion activity
There was no effect of running the test twice: as a group, the
rats were equally active in both tests (main effect of test: F (1,
21) = 1.19, not significant (ns)) and the time course of activity
was also similar in each test (test by time-period interaction: F
(4.72, 99.18) = 1.63, ns).
Overall, modafinil administration resulted in greater LMA
compared to vehicle-treated rats (main effect of dose: F (1,
21) = 49.19, p < 0.05; Fig. 1). Furthermore, as previously ob-
served by Simon et al. (1996), whilst the LMA of control rats
decreased rapidly, that of modafinil-treated rats was less re-
duced (main effect of time-period (F (4.35, 91.25) = 13.91,
p < 0.05); dose by time-period interaction (F (6.73,
141.34) = 4.03, p < 0.05)). Specifically, Bonferroni-corrected
pairwise comparisons showed that modafinil-treated rats were
significantly more active in all time-periods other than the first
compared to vehicle-treated rats: there was a distinct pattern of
reducing activity in the vehicle-treated rats over the course of
the first few time-periods (LMA is significantly lower in all
time-periods after the first, and in most after the second), with
LMA stabilising at the 60–75 min time-period; whereas the
modafinil-treated rats’ LMA barely reduced, differing signif-
icantly only between the first and third time-periods.
Discussion
We have investigated the efficacy of a novel route of admin-
istration, in the form of a suspension in a palatable jelly tablet,
for thermally stable, bio-orally available drugs. We have
shown that modafinil is present in the brain up to at least
150 min after consumption of a 30 mg/kg modafinil-
containing jelly, and that LMA is affected by modafinil on a
similar timescale. This delivery method was presented as a
reduced-stress alternative to oral gavage—a forced oral route
of administration, which elicits undesirable stress responses
and is known to alter an animal’s response to pharmacologi-
cal agents (Brown et al. 2000; Roberts et al. 1995). The re-
sults we obtained from the pharmacokinetic profile of
modafinil concentration in brain tissue show a pattern com-
parable to previously published data from oral administration
of 32 mg/kg modafinil via gavage (Waters et al. 2005). The
concentration levels reported by Waters et al. are, however,
substantially higher at the 30–60-min time-points than those
reported here—although unlike the rats in our study, which
were on our standard food control regime for food-motivated
behavioural testing, their rats were deprived of food overnight
prior to the administration of modafinil. Despite this seeming
discrepancy, both our data and that of Waters et al. demon-
strate a rapid decrease in concentration after the 60-min time-
point. Whilst our data shows a gradual decrease in modafinil
concentration as time progresses, it is clear from Fig. 1 that
our data have high variability in the early time-points, with
the greatest concentration mean at 60 min—the same as re-
ported in Waters et al. Although no statistical analysis of
Waters et al.’s data was presented, the standard deviation data
suggest very high variability at their two highest concentra-
tions—30 and 60 min. Both our study and that of Waters et al.
sampled three rats per time-point, and given the variability in
their data at the highest concentrations reported, we do not
think it reasonable to conclude that there is a substantial dif-
ference between the pharmacokinetic results. Furthermore,
unpublished data from oral gavage using a dose of 64 mg/
kg show a concentration of 350 ng/g modafinil in brain tissue
at 60-min post-administration, although again with high var-
iability (Bundgaard, unpublished observations)—comparing
favourably to our reported 383 ng/g concentration at the same
time-point.
Fig. 1 Locomotor activity: mean ± SEM number of infrared beams
crossed after oral administration of either 30 mg/kg modafinil or vehicle
jellies during time-periods from 15 to 160 min after administration. The
wake-promoting effects of modafinil became obvious after the first time-
period (Bns^ denotes the single time-period where there was no signifi-
cant difference between the groups), following a greater reduction in
exploratory behaviour in the control group. Pharmacokinetic profile:
mean ± SEM ng/g modafinil in brain tissue collected at specific time-
points (within the first 5 mins of the 15 mins LMA time-periods) after oral
administration of 30 mg/kg modafinil. Concentration reduced over time,
although high variability at the 30-min time-point (within the 30–45-min
time-period) may mask a true peak at the 60 min time-point (within the
60–75 min time-period)
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Our data also demonstrate that rats fedmodafinil in jelly form
show LMA that compares favourably to data at a similar dose
after i.p. administration: Simon et al. (1996) report an effect on
LMAafter 40mg/kgmodafinil. As in that study, we have shown
that following actimeter habituation, compared to control per-
formance, modafinil-treated rats exhibited greater LMA overall
and importantly, continuously after the first time-period. Both
our data and that of Simon et al. illustrate a more rapid decline in
LMA in vehicle-treated than modafinil-treated rats, followed by
stabilisation during later time-periods. Our observations differ,
however, in that after the first time-period, modafinil-treated rats
are consistently more active than vehicle-treated—whereas
Simon et al. report differences only at three time-periods: 10–
20, 30–40 and 70–80min. That we usedmore than the twice the
number of subjects, and a within-subjects design, suggests that
lower variability in our sample accounts for our more robust
effect—rather than, for example, a gender or strain effect.
As previously reported by Edgar and Seidel (1997), EEG
recordings support the conclusion that modafinil causes an
increase in LMA only in proportion to the expected time spent
awake, and that LMA intensity is not affected by modafinil. In
contrast, amphetamine-like stimulants not only increase LMA
intensity, but also result in stereotyped behaviours such as
Bcompulsive licking, sniffing, biting, chewing, grooming
and head-waving^ (Duteil et al. 1990). Whilst 300 mg/kg
doses of modafinil do not yield increased LMA intensity in
rats (Edgar and Seidel 1997), 600 mg/kg is reported to result
in Bintense chewing and sniffing… interrupted by brief bursts
of locomotor activity^ (Rowley et al. 2014).
Whilst the aim of jelly administration is to present a stress-
free alternative to gavage as a route of oral administration, we
recognise that our data do not show the effects of any reduction
in stress—given their similarity to published data where either
i.p. or oral gavage administration routes were used. It is the case
that many experiments would not be sensitive to the changes
between stress-free oral administration and gavage/i.p. admin-
istration. However, we consider the obvious benefits of a non-
aversive means of dosing an animal to manifest when using
drugs with a short profile of activity—which might require
multiple dosings during a single experiment. For example, we
have found that rats become reluctant to engage with a task (ID/
ED attentional set-shifting) once they have learned to associate
the task with an i.p. injection—i.e. when we have need to ad-
minister via i.p. in the middle of a test, on subsequent tests, rats
are more reluctant to participate, as the expectation of an injec-
tion affects their interest in the task (Tait and Brown, unpub-
lished observations). Thus, whilst we may not observe the ef-
fects of stress-reduction on the actual data, the benefits for
collecting those data are obvious.
The jelly administration method presents as an alternative to
other oral routes: gavage, syringe-feeding, and the ‘pill’ method
described inWalker et al. (2012). Rich palatability and a capacity
to manufacture a higher volume of pills per batch, makes the
Transgenic Dough Diet a viable alternative to oral gavage, but
the high fat and protein content is less desirable for food-
motivated experiments, and where there is likely to be slower
absorption of a drug because of gastrointestinal contents.
Additionally, the dough diet requires the drug to be kneaded in
(Walker et al. 2012), and therefore final concentration may be
inconsistent as there may be irregular distribution within the
dough unless pills are made individually. Some drugs also re-
quire a solvent to help dissolve them to aid in uniform distribu-
tion, and in some cases a thickening agent was added to the
dough mixture to help finalise it for drying. The benefits, there-
fore, of the individualised jellies is that dosage can be customised
to the weight of the rat without having to make a larger batch,
thereby reducing wastage and being more cost-effective: the gel-
atine mixture is pipetted on top of the pre-weighed drug, which
can remain in crystalline form. Furthermore, multiple rats can be
habituated to/dosed with the jellies simultaneously, without the
need for an experimenter to devote time to individually training/
administering to the rats, as in the syringe-feeding method. As
with other palatable oral methods, any aversive taste the drug
may have should be masked by the palatable flavour of the jelly.
In conclusion, the current data demonstrate the efficacy of a
jelly tablet as a reduced-stress alternative to oral gavage, as
indexed by a pharmacokinetic profile for modafinil compara-
ble to previous data from gavage administration, and an LMA
profile comparable to previous i.p. administration of
modafinil. Reducing stress-related arousal during the admin-
istration of pharmacological agents is a fundamental refine-
ment to drug administration—and should be a goal for ethical
experimentation regardless of any benefit to the data. Thus,
whilst this technique should hopefully remove unwanted be-
havioural consequences that may mask the effects of a drug, it
also promotes an overall ethical responsibility of reducing
pain and distress in experimental animals.
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